Search results for " transitional cell"

showing 10 items of 58 documents

LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TU…

1998

Purpose: The role of a combined regimen of local hyperthermia and topical chemotherapy in patients with multifocal and recurrent superficial bladder tumors not curable by transurethral resection was evaluated in a neodjuvant organ sparing clinical study. Materials and Methods: A total of 19 patients with multifocal, superficial grades 1 to 3 bladder tumors that recurred after intravesical chemoprophylaxis or immunoprophylaxis underwent local combined administration of microwave induced hyperthermia and intravesical chemotherapy as a debulking approach. Due to extensive superficial involvement of the bladder walls complete transurethral resection of all tumors seemed technically unfeasible i…

HyperthermiaAdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyAntineoplastic AgentsCystectomyBladder NeoplasmmedicineHumansMicrowavesAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryintravesical chemotherapy bladder cancer microwave hyperthermiaHyperthermia InducedMiddle Agedmedicine.diseaseDebulkingSurgeryRegimenmedicine.anatomical_structureAdministration IntravesicalUrinary Bladder NeoplasmsChemoprophylaxisFeasibility StudiesFemaleNeoplasm Recurrence LocalbusinessThe Journal of Urology
researchProduct

Podoplanin serum and urine concentration in transitional bladder cancer

2016

Background Podoplanin (PDP) is a mucin - a type of transmembrane protein expressed in numerous tissues during ontogeny and in adult animals, including the brain, heart, kidney, osteoblasts and lymphoid organs. Objective The aim of this study was to determine podoplanin concentration in the blood serum and urine of patients with bladder cancer. Quantifying podoplanin concentration and its correlation with various clinicopathological parameters may be useful for more accurate predictions and identifying high-risk patients. Methods The present study included 82 patients with bladder cancer confirmed by transurethral resection or cystectomy and 27 healthy volunteers. The Surface Plasmon Resonan…

Male0301 basic medicineCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentUrineCystectomy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBlood serumBiomarkers TumorGeneticsmedicineHumansAgedNeoplasm StagingCarcinoma Transitional CellKidneyCreatinineMembrane GlycoproteinsBladder cancerbusiness.industryGeneral MedicineMiddle AgedSurface Plasmon Resonancemedicine.disease030104 developmental biologymedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsOncologyPodoplaninchemistryCreatinine030220 oncology & carcinogenesisFemalebusinessCancer Biomarkers
researchProduct

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions

2004

Abstract Objectives To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations. Methods A total of 27 patients were treated with intravesical gemcitabine after transurethral resection during which one to three papillary marker lesions were left unresected. Starting 14 days after transurethral resection, six instillations of gemcitabine were given at weekly intervals. Gemcitabine, diluted in 50 mL of saline solution and maintained for 2 hours, was given at the dose of 500 mg, 1000 mg, and 2000 mg in groups of 9 patients each. A complete response (CR) was defined as negative cytology, cystosco…

MaleAntimetabolites Antineoplasticmedicine.medical_specialtyUrologyUrinary systemUrologySalvage therapyDeoxycytidineDisease-Free SurvivalSettore MED/24 - UrologiamedicineCarcinomaHumansProdrugsAgedSalvage TherapyCarcinoma Transitional CellUrinary bladderDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryRemission InductionCystoscopyMiddle Agedmedicine.diseaseGemcitabineGemcitabineGemcitabineSurgeryAdministration IntravesicalTreatment Outcomemedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsTolerabilityFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drug
researchProduct

The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.

2018

BACKGROUND We examined the expression of CD200, a ligand of immune tolerance, in transitional cell carcinoma of the human bladder (TCC). MATERIALS AND METHODS CD200 was analyzed by immunohistochemistry (IHC) in 90 patients with suspected TCC lesions of the bladder. Expression of CD200 was exemplarily validated by quantitative reverse transcription polymerase chain reaction and western blot analysis. RESULTS CD200 was detectable at mRNA and protein levels in TCC homogenate and TCC cell lines (T24, UMUC3). TCC tissues showed significantly higher CD200 expression (p<0.005) than normal bladder tissues. CD200 signals were also higher in metastasized compared to localized TCC (p<0.05). CD200 was …

MaleCancer Researchmedicine.medical_treatmenturologic and male genital diseasesMetastasis03 medical and health sciences0302 clinical medicineWestern blotAntigens CDmedicineBiomarkers TumorHumansRNA MessengerRNA NeoplasmNeoplasm MetastasisneoplasmsAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellBladder cancermedicine.diagnostic_testbusiness.industryCell DifferentiationGeneral MedicineImmunotherapymedicine.diseasefemale genital diseases and pregnancy complicationsImmune checkpointNeoplasm ProteinsReverse transcription polymerase chain reactionTransitional cell carcinomaOncologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleTumor EscapeNeoplasm Gradingbusiness030215 immunologyAnticancer research
researchProduct

Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?

2003

Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. T…

MaleCarcinoma Transitional CellCancer ResearchATP Binding Cassette Transporter Subfamily BBladder carcinomaImmunohistochemistryIntravesical chemotherapySettore MED/24 - UrologiaAdministration IntravesicalUrinary Bladder NeoplasmsOncologyDrug Resistance NeoplasmPredictive Value of TestsGP-170HumansFemaleMDR-1ChemoresistanceGlycoproteinsNeoplasm StagingRetrospective Studies
researchProduct

Studies on the Intravesical Action of Topically Administered G 3 H-Doxorubicin Hydrochloride in Men: Plasma Uptake and Tumor Penetration

1980

AbstractDoxorubicin hydrochloride has been used for the treatment and prevention of recurrences of transitional cell carcinoma. Ideal indications for the drug and side effects have not been determined. In this regard the penetration of the drug into the bladder wall and the urothelium as a urinary blood barrier is of interest. Using a tritium label we have investigated tumor penetration and transmucosal plasma uptake of doxorubicin hydrochloride after intravesical application in 7 patients with stage A bladder tumors. Of the 7 patients 5 were free of tumor following transurethral resection and 2 had recurrent disease. The patients free of tumor received 40mg. doxorubicin hydrochloride per 3…

MaleDrugmedicine.medical_specialtyPathologyHydrochlorideAdministration TopicalUrologymedia_common.quotation_subjectUrinary systemmedicine.medical_treatmentUrinary BladderUrologychemistry.chemical_compoundHumansMedicineUrotheliumSalinemedia_commonCarcinoma Transitional Cellbusiness.industryPapillary tumorMiddle Agedmedicine.diseaseTransitional cell carcinomaUrinary Bladder NeoplasmschemistryDoxorubicinDoxorubicin HydrochlorideNeoplasm Recurrence LocalbusinessJournal of Urology
researchProduct

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

2016

Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions. Cumulative and 6-month VTE incidence rates were determined. The association of first-line chemotherapy (divided into six groups) and other baseline characteristics on VTE were anal…

MaleOncologyCancer Researchmedicine.medical_treatmentDisease030204 cardiovascular system & hematologyDeoxycytidine0302 clinical medicineNeoplasm MetastasisOriginal ResearchIncidenceIncidence (epidemiology)Middle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesischemotherapy survivalbladder cancerFemaleBufeta -- Càncermedicine.drugAdultmedicine.medical_specialtyMetastatic Urothelial Carcinomavenous thromboembolismAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineUrothelialmedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesAgedRetrospective StudiesTrombosi -- TractamentGynecologyCisplatinCarcinoma Transitional CellChemotherapyBladder cancerbusiness.industryClinical Cancer ResearchCancermedicine.diseaseequipment and suppliesSurvival AnalysisGemcitabineGemcitabineUrinary Bladder NeoplasmsUrothelial;Cisplatinbusiness
researchProduct

Second-Line Chemotherapy in Advanced Bladder Cancer

2000

MaleOncologyCarcinoma Transitional Cellmedicine.medical_specialtyClinical Trials Phase I as Topicbusiness.industryUrologyMiddle AgedGenes p53VinblastineSecond line chemotherapyClinical Trials Phase II as TopicMethotrexateUrinary Bladder NeoplasmsDoxorubicinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAdvanced bladder cancerHumansMedicineFemaleCisplatinbusinessAgedUrologia Internationalis
researchProduct

Multiple Mucosal Biopsies and Postoperative Urinary Cytology in Patients with Bladder Cancer

1990

Seventy-one patients with bladder tumors of stage Ta, T1 or T2 were studied by bladder mucosal biopsies. In 34 (48%) patients abnormal histology was found in at least one of the biopsies. The occurrence and severity of mucosal abnormalities were related to tumor grade and stage. Urinary cytology after complete tumor resection was positive in 18 of 19 patients with abnormal biopsies and in 6 of 12 patients with normal biopsies. Postoperative urinary cytology seems to be a good indicator for the presence of urothelial atypia.

MalePathologymedicine.medical_specialtyBiopsyUrologyUrinary systemUrinary BladderUrologyCytologyBiopsyAtypiamedicineHumansCarcinoma Transitional CellMucous MembraneUrinary bladderBladder cancermedicine.diagnostic_testbusiness.industryCarcinoma in situMiddle Agedmedicine.diseaseNeck of urinary bladdermedicine.anatomical_structureUrinary Bladder NeoplasmsFemalebusinessCarcinoma in SituEuropean Urology
researchProduct

Urine cytology, tumour markers and bladder cancer

1998

MalePathologymedicine.medical_specialtyUrologyUrineAntigens NeoplasmBiomarkers TumorHumansMedicineAcidic Fibroblast Growth FactorGrowth SubstancesUrine cytologyCarcinoma Transitional CellBladder cancerUrinary bladdermedicine.diagnostic_testbusiness.industryMedical screeningmedicine.diseaseTumor associated antigenmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsBlood Group AntigensFemaleHistopathologybusinessBJU International
researchProduct